Payne becomes RSSL’s investigational partner

Provides support in addressing manufacturer’ problems

RSSL has appointed Philip Payne as its new investigative partner, providing manufacturers of pharmaceuticals, APIs and excipients with support in addressing problems that have led to 'out of specification' test results.

Payne will provide hands-on quality and process improvement support, addressing quality issues within the client's own site and across their supply chain. RSSL can also provide training in topics such as GMP, GDP and quality management, as well as auditing to lead assessor and internal corporate standards.

Payne joined RSSL in 2007 as business development manager and since joining has boosted membership of RSSL's Emergency Response Service, which provides immediate analytical support to manufacturers at a time of a product crisis. He previously worked for Italian API producer Steroid, in a variety of technical roles.

You may also like

Ingredients

Guidance on gluten labelling of pharmaceutical products

This white paper considers the FDA’s guidance on gluten labelling within the pharmaceutical sector, whilst also reflecting on RSSL’s extensive experience and expertise in allergen management and testing
Training & Education

New course in API auditing

Audit of API manufacturing is a key skill requirement for every Qualified Person
Ingredients

Examining excipients

Adulteration of excipients is of growing concern in today’s global supply chain and the US Pharmacopeia has made several changes to protect patients. Philip Payne, investigative partner of testing laboratory RSSL, highlights the latest requirements
Ingredients

Ingredients & integrity

<p>Contamination and counterfeits present a real and growing threat to pharmaceutical companies.<strong> Philip Payne</strong>, RSSL Pharma business development manager, discusses how working with a contract lab can prevent a major product recall or worse disaster</p>
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Ingredients

Pangea Pharmaceuticals launches FDA-approved amlodipine oral solution Sdamlo

Pangea’s Sdamlo, the first FDA-approved amlodipine powder for oral solution, leverages a patent-pending lyophilisation process to enable precise unit-dose delivery and improved administration for paediatric, geriatric and dysphagic patients
Ingredients

Oncodesign Services extends GIP ARRONAX collaboration to secure astatine-211 supply

The company has extended its collaboration with the French radionuclide specialist to secure access to astatine-211, an alpha-emitting radioisotope of growing interest in targeted radiotherapy but constrained by its seven-hour half-life and limited production capacity
Subscribe now